Skip to main content

Table 1 Comparison of demographics and clinical factors between General and Study Cohorts

From: Combined chemoradiotherapy showed improved outcome with early-stage HPV-positive oropharyngeal cancers

Variables, no. (%) General Cohort (n = 727) Study Cohort (n = 244) p-value p16-positive (n = 189) p16-negative (n = 55) p-value
Age, years (Mean ± SD) 60.1 ± 10.5 57.3 ± 9.4 < 0.01 56.4 ± 9.2 60.3 ± 9.5 < 0.01
Sex    0.53    0.21
 Male 569 (78.3) 186 (76.2)   148 (78.3) 38 (69.1)  
 Female 158 (21.7) 58 (23.8)   41 (21.7) 17 (30.9)  
Anatomical sitea    < 0.01    0.03
 Tonsil 314 (43.2) 190 (77.9)   153 (81.0) 37 (67.3)  
 Base of tongue 311 (42.8) 48 (19.7)   33 (17.5) 15 (27.3)  
 Other oropharynxb 98 (13.5) 5 (2.0)   2 (1.1) 3 (5.5)  
Smoking historyc    0.22    < 0.01
 Never-smoker 137 (18.8) 54 (22.1)   49 (25.9) 5 (9.1)  
 Ever-smoker 590 (81.2) 186 (76.2)   137 (72.5) 49 (89.1)  
Primary treatment    0.37    0.22
 RT 430 (59.1) 136 (55.7)   101 (53.4) 35 (63.6)  
 CRT 297 (40.9) 108 (44.3)   88 (46.6) 20 (36.4)  
5-year survival    0.06    < 0.01
 Alive 451 (62.0) 168 (68.9)   142 (75.1) 26 (47.3)  
 Died of disease 168 (23.1) 53 (21.7)   36 (19.0) 17 (30.9)  
 Died of other cause 108 (14.9) 23 (9.4)   11 (5.8) 12 (21.8)  
  1. Abbreviations: RT Radiotherapy, CRT Concurrent chemoradiotherapy
  2. aUnknown primary (n = 5)
  3. bIncludes: Soft palate (n = 48), Oropharyngeal wall (n = 32), Vallecula (n = 14), Uvula (n = 8), Anterior surface of epiglottis (n = 1)
  4. cUnknown smoking status (n = 4)